A Prospective, Randomized, Open-Label, Blinded Endpoint Evaluation (PROBE) Parallel Group Study Comparing Edoxaban vs. VKA in Subjects Undergoing Catheter Ablation of Non-valvular Atrial Fibrillation (ELIMINATE-AF)
Latest Information Update: 19 Feb 2024
At a glance
- Drugs Edoxaban (Primary) ; Acenocoumarol; Fluindione; Phenprocoumon; Warfarin
- Indications Cardiovascular disorders; Stroke
- Focus Adverse reactions; Therapeutic Use
- Acronyms ELIMINATE-AF
- Sponsors Daiichi Sankyo Europe
- 11 Apr 2019 Results published in the European Heart Journal
- 18 Mar 2019 Primary endpoint (Number of participants who experienced composite of all-cause death, stroke and major bleeding defined by the International Society on Thrombosis and Hemostasis (ISTH)) has been met.
- 18 Mar 2019 According to a Daiichi Sankyo Company media release, Late-breaking data presented at EHRA 2019, the annual congress of the European Heart Rhythm Association